Annovis Bio, Inc. (ANVS) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.00
↓-100% vs avg
5yr avg: 3.37
30Y Low0.0·High6.6
ROE
↑
-0.3%
↓+100% vs avg
5yr avg: -766.2%
30Y Low-72%·High-0%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANVS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Annovis Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $65M | $71M | $62M | $169M | $110M | $134M | $48M | — | — | — |
| Enterprise Value | $-19467060066 | $-19461228080 | $51M | $163M | $81M | $88M | $39M | — | — | — |
| P/E Ratio → | -1.71 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | 6.61 | — | 3.87 | 3.01 | 6.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ANVS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
ANVS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -0.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.3% | -0.3% | -3159.1% | -546.4% | -69.6% | -55.7% | -72.4% | — | — | — |
| ROA | -0.3% | -0.3% | -203.8% | -243.1% | -61.8% | -53.5% | -118.3% | -169.7% | -349.2% | -190.5% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
| ROCE | -0.3% | -0.3% | -334.2% | -263.0% | -70.1% | -55.9% | -199.8% | — | — | — |
ANVS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $19.5B exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.16 | -1.13 | — | -1.00 | -1.03 | -1.07 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -802.48 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -14.40 | — | — | — | -0.14 | — | -10818.18 | -8119.05 |
Net cash position: cash ($19.5B) exceeds total debt ($0)
ANVS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Annovis Bio, Inc.'s current ratio of 5.37x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.39x to 5.37x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.37 | 5.37 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 | 0.09 | 0.73 |
| Quick Ratio | 5.37 | 5.37 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 371.20 | 0.09 | 0.73 |
| Cash Ratio | 5.37 | 5.37 | 2.72 | 1.34 | 3.69 | 30.33 | 13.96 | 0.00 | 0.06 | 0.71 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
ANVS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Annovis Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $21M | $12M | $9M | $8M | $8M | $6M | $7M | $4M | $4M |
Peer Comparison
Compare ANVS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANVSYou | $65M | -1.7 | — | — | — | — | -0.3% | — | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 PRTA | $602M | -2.5 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AVXL | $310M | -6.2 | — | — | — | — | -43.1% | — | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See ANVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANVS vs SAVA
Side-by-side business, growth, and profitability comparison vs Cassava Sciences, Inc..
Start ComparisonANVS — Frequently Asked Questions
Quick answers to the most common questions about buying ANVS stock.
What is Annovis Bio, Inc.'s P/E ratio?
Annovis Bio, Inc.'s current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
What is Annovis Bio, Inc.'s ROE?
Annovis Bio, Inc.'s return on equity (ROE) is -0.3%. The historical average is -49.5%.
Is ANVS stock overvalued?
Based on historical data, Annovis Bio, Inc. is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.